Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Top Breast Cancer Research Findings for the Past Year

March 9th 2015

A new standard that recommends ovarian function suppression (OFS) therapy as a routine adjuvant treatment option for certain premenopausal women with higher risk, hormone receptor (HR)â€“positive breast cancer emerged as the most far-reaching medical oncology research finding in the field for 2014, according to Debu Tripathy, MD.

Dr. Schilling on Dense Breast Tissue Detection Methods

March 6th 2015

Kathy J. Schilling, MD, a radiologist at Boca Raton Regional Hospital, discusses the importance of additional screening for women with dense breasts.

Balancing Act: Calculating Adjuvant Treatment Risks in Older Women With Breast Cancer

March 6th 2015

Hyman B. Muss, MD, provides expert insight on adjuvant treatment for older patients with breast cancer.

Carey Offers Views on Evolving Chemotherapy Options-and Beyond-in TNBC

March 5th 2015

OncLive spoke with Lisa A. Carey, MD, professor at the University of North Carolina Chapel Hill, about recent developments for patients with triple-negative breast cancer.

Dr. Schilling on Screening for Breast Cancer

March 4th 2015

Kathy Schilling, MD, radiologist, Christine E. Lynn Women's Health & Wellness Institute at Boca Raton Regional Hospital, discusses screening methods for breast cancer.

Dixon Questions Value of Chemoprevention With Tamoxifen

March 3rd 2015

The reduction of breast cancer risk with 5 years of tamoxifen does not outweigh the lack of a mortality benefit, according to J. Michael Dixon, MD, OBE, who shared his view in a session at the 32nd Annual Miami Breast Cancer Conference.

Top MBCC Abstracts Focus on Tumor Profiling and Radiotherapy Paradigms

March 2nd 2015

A detailed tumor profile of molecular and protein alterations in a rare breast cancer subtype and a retrospective analysis about the impact of radiation after breast conserving surgery took home top honors at the Miami Breast Cancer Conference this year.

US Lags in Adopting Hypofractionated Radiation Standard

March 2nd 2015

Compelling clinical trial evidence supports the use of hypofractionated radiation as the standard of care for postmenopausal women with luminal A tumors and node-negative disease.

Dr. Pegram on Challenges in Neoadjuvant Treatment for HER2-Positive Breast Cancer

February 28th 2015

Mark D. Pegram, MD, associate director, clinical research, director, Breast Cancer Program, Stanford Cancer Institute, goes over some of the challenges surrounding neoadjuvant treatment for HER2-positive breast cancer patients.

Dr. Muss on Optimizing Adjuvant Treatment for Older Breast Cancer Patients

February 28th 2015

Hyman B. Muss, MD, professor of oncology, University of North Carolina, director, Geriatric Oncology, Lineberger Comprehensive Cancer Center, discusses optimizing adjuvant treatment in older patients with breast cancer.

Joan Lunden Paints a Picture of Breast Cancer From the Patient's Perspective

February 28th 2015

Joan Lunden presented the keynote address at the Miami Breast Cancer Conference where she spoke powerfully and from the heart in a talk perfectly aligned with the meeting's focus on the patient perspective.

Heterogeneity Complicates Treatment Decisions in Breast Cancer

February 28th 2015

Heterogeneity, which can result in treatment resistance, is commonly underestimated and misunderstood, representing an important area of future research.

Hudis Highlights Interplay Between Inflammation, Obesity, and Breast Cancer

February 28th 2015

In a discussion at the Miami Breast Cancer Conference, Clifford A. Hudis, MD, suggested that an increased risk for developing breast cancer might be a consequence of inflammation that often accompanies obesity.

Dr. Sledge on Using Tumor Heterogeneity to Guide Treatment in Breast Cancer

February 28th 2015

George W. Sledge, Jr., MD, professor of medicine, Stanford University School of Medicine, explains how tumor heterogeneity impacts patient care and research.

Dr. Carey on Treating Triple-Negative Breast Cancer

February 28th 2015

Lisa A. Carey, MD, professor of medicine, Breast Cancer Research, University of North Carolina, medical director, UNC Breast Center, chief of Hematology/Oncology, physician-in-chief, UNC North Carolina Cancer Hospital, discusses treatment options and challenges in triple-negative breast cancer.

Early Intervention Essential for Proper Lymphedema Management

February 27th 2015

Moving early to diagnose and treat lymphedema after breast cancer treatment can reverse this side effect or prevent it from becoming more severe.

Driver Mutations Remain Prognostic But Not Predictive in Breast Cancer

February 27th 2015

Tumor genome profiling identifies driver mutations in breast tumors, however, it is still too early to use this information in clinical decision making.

Neoadjuvant Endocrine Therapy Appropriate in Select Patients

February 27th 2015

While not appropriate for all patients with ER-positive breast cancer, neoadjuvant endocrine therapy could play an important role in select groups of women with comorbidities or those with ER-rich/luminal A disease.

Excitement Building for PARP Inhibitors in BRCA-Mutated Breast Cancer

February 27th 2015

The FDA's recent approval of the first PARP inhibitor suggests that this new class of targeted therapy has great potential to help not only patients with ovarian cancer for whom the agent is indicated but also individuals with breast cancer.

Dr. Tripathy on the Possibility of Curing Metastatic Breast Cancer

February 26th 2015

Debu Tripathy, MD, professor of medicine, chair, department of breast medical oncology, The University of Texas MD Anderson Cancer Center, discusses the possibility of one day being able to cure metastatic breast cancer.